Skip to content
Dosage GuideResearch Reference

VIP (Vasoactive Intestinal Peptide) Dosage

Research-based dosing protocols, timing guidance, and reconstitution reference for VIP (Vasoactive Intestinal Peptide). All information is for educational purposes only.

Quick Answer

VIP is typically administered via subcutaneous injection, intranasally, or intravenously. Dosages vary widely in research. No standardized human dose-ranging trials are completed. Clinical use is largely investigational.

→ VIP (Vasoactive Intestinal Peptide) Benefits→ VIP (Vasoactive Intestinal Peptide) Side Effects→ Full VIP (Vasoactive Intestinal Peptide) Profile
Table of Contents

Standard Dosage Range

Research dosing range: 10–150 mcg per dose (subcutaneous or intranasal); IV administration in hospital settings only.

Educational reference only

These dosage ranges are derived from preclinical research and community protocols. No human clinical dose-ranging trials have established therapeutic doses for most research peptides. Always consult a qualified healthcare provider before starting any peptide protocol.

Dosage by Use Case

Chronic Inflammatory Response Syndrome (CIRS)

50 mcg1–2× daily
Duration

1–3 months

Typically administered intranasally. Used as part of the Shoemaker protocol. Effectiveness varies; some patients report significant benefit, others minimal.

Asthma / Bronchospasm

25–75 mcgAs needed
Duration

Single dose

Administered via nebulizer or intranasally. Efficacy as a rescue medication is not well established.

Pulmonary Hypertension

50–150 mcg2–3× daily
Duration

Ongoing

Subcutaneous injection. Used to reduce pulmonary artery pressure. Requires close monitoring by a physician.

Autoimmune Conditions (Investigational)

10–50 mcg1× daily
Duration

4–12 weeks

Subcutaneous injection. Mechanism is based on VIP's immunomodulatory effects. Clinical evidence is limited.

Timing & Frequency

Administer consistently at the same time each day. For CIRS, often administered in the morning and evening. For pulmonary conditions, may be administered before activities that trigger symptoms.

Cycle Guidance

Cycle duration is highly variable and depends on the individual’s condition and response to treatment. Some patients remain on VIP indefinitely for chronic conditions, while others cycle on and off. Monitoring by a physician is essential.

Reconstitution Reference

Quick reference for reconstituting VIP (Vasoactive Intestinal Peptide). For custom vial sizes and concentrations, use the Reconstitution Calculator.

Common Vial SizeTypically 50 mcg or 100 mcg per vial
BAC Water Volume1 mL bacteriostatic water
Concentration & DrawAt 1 mL: 50 mcg/mL or 100 mcg/mL
StorageRefrigerate at 2–8°C after reconstitution. Keep lyophilized powder at room temperature or refrigerated.
StabilityReconstituted solution is highly unstable; use immediately after reconstitution. Lyophilized powder stable 12-24 months per manufacturer specifications.
Use the Reconstitution Calculator → for precise injection volumes based on your exact vial size, water volume, and desired dose.

Frequently Asked Questions

What is VIP primarily used for?
VIP is used in integrative medicine, primarily for Chronic Inflammatory Response Syndrome (CIRS). It is also being investigated for conditions like asthma, pulmonary hypertension, and autoimmune diseases.
How is VIP administered?
VIP is most commonly administered via intranasal spray or subcutaneous injection. IV administration is sometimes used in clinical settings.
What are the potential side effects of VIP?
Common side effects include hypotension, flushing, and dizziness due to vasodilation. Severe reactions are rare but possible. Individuals should consult a doctor before using VIP.
How long does VIP take to work?
The onset of action is relatively rapid, especially with intranasal administration. However, the full effects may take several weeks to manifest.
Is VIP FDA-approved?
No, VIP is not FDA-approved for any specific indication. It is used off-label by some practitioners.

Last updated: 2026-02-19